GLP-1 Medications and Surgery: Pre-Op Discontinuation Guidelines

Why GLP-1s and surgery are a real consideration

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide (Byetta, Bydureon) — work in part by slowing how quickly food leaves the stomach. This delayed gastric emptying is what produces the prolonged satiety patients experience after meals.

It also means that hours after a meal, the stomach may still contain significant residual food and liquid — even when the patient feels empty. Under general anesthesia, when normal protective reflexes (gag reflex, cough reflex, swallowing coordination) are suppressed, retained stomach contents can be regurgitated and aspirated into the lungs. Aspiration during anesthesia is a serious complication — it can cause aspiration pneumonia, acute respiratory distress, and in rare cases is fatal.

This isn't a theoretical concern. By 2023, anesthesiologists across the U.S. were reporting unusually high rates of unexpected gastric content during GLP-1 patients' procedures, including patients who had followed standard NPO (nothing by mouth) guidelines.

The 2023 ASA guidance — hold the dose

In June 2023, the American Society of Anesthesiologists issued a consensus-based guidance that became the de facto standard:

• Daily GLP-1s (liraglutide Saxenda/Victoza, exenatide Byetta) — hold the day of surgery.
• Weekly GLP-1s (semaglutide, tirzepatide, dulaglutide, exenatide Bydureon) — hold the dose for one week before surgery.
• If holding was not possible or didn't happen, treat the patient as having a full stomach: ultrasound assessment of gastric contents, rapid-sequence induction, and other aspiration-precaution techniques.

This guidance was conservative by design — anesthesiologists prioritized aspiration safety over the modest risks of one missed GLP-1 dose. The reaction in surgical and metabolic-medicine communities was mixed; some clinicians felt the week-long hold was excessive, particularly for diabetic patients whose glycemic control could suffer.

The 2024 multi-society update — more nuanced

In October 2024, a joint statement from the ASA, the American Society for Metabolic and Bariatric Surgery, and several other organizations softened the recommendation toward individualized assessment:

• Routine cessation may not be necessary for all GLP-1 patients before elective surgery, particularly when the procedure is short and aspiration risk is otherwise low.
• Liquid clear diet for 24 hours before surgery may be sufficient mitigation in many cases.
• Ultrasound assessment of gastric contents on the day of surgery can guide the decision in real time.
• Patients on lower doses or shorter-acting GLP-1s may need less aggressive discontinuation than those on high-dose Wegovy or Zepbound.
• The anesthesia team makes the final call based on the specific procedure, patient, and presentation.

The 2024 update reflected a year of accumulated clinical experience and pragmatic adjustments. It is not a reversal of the 2023 guidance so much as a recognition that one-size-fits-all rules don't fit a class with varied half-lives, doses, and patient profiles.

What patients should actually do

The practical patient checklist for any scheduled surgery while on a GLP-1:

1. Tell your surgeon and the pre-op team early. List GLP-1 medications on every intake form and remind them during the pre-op visit. Surgeons sometimes ask about medications routinely without specifically prompting about weight-loss drugs.

2. Confirm the discontinuation plan with the anesthesia team. The surgeon may defer this decision to anesthesia. Many practices have settled on the following defaults for ELECTIVE surgery requiring general anesthesia:

• Weekly GLP-1: skip the dose due 7 days before surgery (one missed weekly dose).
• Daily GLP-1: hold the day of surgery.
• Clear liquids for 24 hours before; standard NPO for 8 hours.

3. Follow standard NPO guidance more strictly than you might otherwise. Even with the dose held, GLP-1s' effects linger — semaglutide and tirzepatide have half-lives of about a week. Treating yourself as having a full stomach until proven otherwise is the conservative right move.

4. Plan for glycemic management during the hold. For diabetic patients, especially those whose insulin regimen depends on GLP-1 effect, the surgical team and your endocrinologist may need to adjust other medications during the hold week.

5. Resume GLP-1 after surgery per your prescriber's guidance. Usually within a few days post-op, when normal eating resumes — but the timing depends on the procedure.

Emergency vs elective — different framing

The guidance above applies to elective surgery, where the schedule allows holding doses in advance.

Emergency surgery is a different situation entirely. There is no time to discontinue, and the anesthesia team is going to manage the aspiration risk directly through technique — rapid-sequence induction, ultrasound assessment, careful intubation, and increased monitoring. Patients in this situation should make sure the surgical and anesthesia teams know about the GLP-1; the team handles the rest.

Procedures that don't require general anesthesia

The aspiration concern is specific to general anesthesia. Procedures performed under local anesthesia, sedation that maintains airway reflexes, or regional anesthesia (spinal, epidural) without GA have very different risk profiles — GLP-1 discontinuation is generally not required for these.

This includes most minor procedures — dermatology, dental work, eye surgery, many endoscopies. Confirm with the specific provider, but routine GLP-1 use is usually fine for non-GA procedures.

The honest read

GLP-1 medications and elective surgery require a deliberate conversation between the patient, the prescriber, and the surgical team. The 2024 guidance is more flexible than the 2023 version, but the underlying physiology hasn't changed — these drugs slow gastric emptying, and the safest approach for elective surgery under general anesthesia is to hold the dose appropriately and treat the patient with full-stomach precautions even after holding.

The thing patients can do that makes the biggest difference: tell every provider you take a GLP-1, every time, even for procedures that seem unrelated. The clinical infrastructure is still catching up to how widespread these medications have become, and patient self-advocacy is often what closes the gap.